Aurobindo Pharma Receives US FDA Form 483 with Five Procedural Observations at Apitoria Pharma Unit-I

Aurobindo Pharma Limited announced the completion of the US Food and Drug Administration (US FDA) inspection at Unit-I of its wholly owned subsidiary, Apitoria Pharma Private Limited. The inspection, conducted from August 21 to August 29, 2025, involved the Active Pharmaceutical Ingredient (API) manufacturing facility located in Borpatla Village, Telangana.

Following the inspection, the US FDA issued a Form 483 containing five observations, all procedural in nature. Importantly, there were no data integrity issues identified—a critical aspect ensuring compliance with FDA standards. The company clarified that it will respond to the US FDA within the stipulated timeline, addressing each observation comprehensively.

Aurobindo Pharma emphasized that the FDA's observations are part of the routine inspection process and the current action will not affect the company’s financial health or ongoing operations. The company reiterates its commitment to maintaining the highest manufacturing quality standards across its global facilities.

Investors and stakeholders will be closely monitoring the company’s corrective action plan and subsequent FDA reviews, critical for maintaining Aurobindo Pharma’s market reputation and continued access to key pharmaceutical markets.

Key Highlights:

US FDA inspected Apitoria Pharma’s Unit-I API facility in Telangana from August 21-29, 2025.

Form 483 issued with five procedural observations; no data integrity concerns reported.

Company committed to responding within FDA’s regulatory timeframe.

No expected financial or operational impact due to the inspection outcome.

Inspections reaffirm Aurobindo Pharma's focus on regulatory compliance and quality standards.

Sources: NSE India, Aurobindo Pharma official disclosure, Medical Dialogues, Business Upturn